VeriMomIst dihydromyricetin in der Schwangerschaft sicher?
No harmonised CLP reproductive classification (ECHA Annex VI) and no SCCS/CIR safety assessment raising reproductive concerns were identified. PubMed literature on dihydromyricetin (ampelopsin) focuses on antioxidant, hepatoprotective and metabolic effects; I found no convincing animal or human reproductive toxicity or teratogenicity data. Topical cosmetic absorption is expected to be low but measurable for a small polar flavonoid, so exposure is scored as low (evidence sources: PubMed, PubChem, CosIng, ECHA Annex VI absence).
Pregnancy-safe products containing dihydromyricetin
Related ingredients
Frequently asked questions
- Ist dihydromyricetin in der Schwangerschaft sicher?
- No harmonised CLP reproductive classification (ECHA Annex VI) and no SCCS/CIR safety assessment raising reproductive concerns were identified. PubMed literature on dihydromyricetin (ampelopsin) focuses on antioxidant, hepatoprotective and metabolic effects; I found no convincing animal or human reproductive toxicity or teratogenicity data. Topical cosmetic absorption is expected to be low but measurable for a small polar flavonoid, so exposure is scored as low (evidence sources: PubMed, PubChem, CosIng, ECHA Annex VI absence).
- Ist dihydromyricetin während des Stillens sicher?
- No data indicating reproductive or lactation-specific toxicity or harmonised classifications. No demonstrated mechanism for transfer into milk; systemic exposure from topical use is likely low but measurable, so breastfeeding exposure is scored low (PubMed, PubChem, CosIng; no CIR/SCCS flags).
- Ist dihydromyricetin sicher für Babyhaut?
- No infant-specific toxicity or developmental skin studies were identified. Hazard and mechanistic scores remain 0 due to absence of reproductive/endocrine evidence. Because infant skin has higher permeability and surface-area-to-weight, exposure is increased by +1 versus adult (adult e=1 → infant e=2) for measurable-absorption ingredients (sources: PubMed, CosIng, EWG; no harmonised CLP or SCCS/CIR restrictions).
- Wie bewertet VeriMom dihydromyricetin?
- VeriMom bewertet dihydromyricetin mit 93/100 (keine bekannten Risiken) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu dihydromyricetin?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu dihydromyricetin basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.